At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

Clinical Regulatory News Trials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).

October 17, 2025

Vol.51 No.38

By Edison T. Liu

News Analysis Regulatory News

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Bowing to the growing animal rights movement, FDA and NIH have made policy changes to discourage animal testing, instead favoring alternative research models.

October 17, 2025

Vol.51 No.38

By Claire Marie Porter and Jacquelyn Cobb

Drugs & Targets

FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment

FDA has received reports of immune effector cell-associated enterocolitis in patients who received treatment with Carvykti.

October 17, 2025

Vol.51 No.38

Drugs & Targets

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

FDA has granted a approval for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a maintenance treatment for adults with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

October 03, 2025

Vol.51 No.36

Drugs & Targets

FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

FDA has approved Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.

October 03, 2025

Vol.51 No.36

Drugs & Targets

FDA grants Fast Track Designation to UB-VV111 in vivo CAR T-cell therapy

FDA has granted Fast Track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma following two or more lines of prior therapy and relapsed/refractory chronic lymphocytic leukemia following two or more lines of prior therapy.

October 03, 2025

Vol.51 No.36

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

YOU MAY BE INTERESTED IN

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

FDA grants Fast Track Designation to UB-VV111 in vivo CAR T-cell therapy

Renew today!

Subscriber content

Never miss an issue!

Login

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

YOU MAY BE INTERESTED IN

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

FDA grants Fast Track Designation to UB-VV111 in vivo CAR T-cell therapy

Never miss an issue!

Login

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough